Recall inflammatory skin reaction after use of pegylated liposomal doxorubicin in site of previous drug extravasation

摘要

Evidence from predinical and clinical data suggests that pegylated liposomal doxorubicin accumulates preferentially in tissues -with, increased microvascular permeability because of the leaky vasculature, which exists for most tumours with active neoangiogenesis.' Unfortunately, stealth liposomes also accumulate in healthy and susceptible tissues, including the skin and the mucosa. This unusual pharmacokmetic characteristic accounts for the unique toxic-effect profile of pegylated liposomal doxorubicin, which is characterised by dominant and dose-limiting mucocutaneous toxic effects, mild myelosuppression, some alopecia, but no apparent clinical or functional cardiac-related toxic effects.